Promising drug combo aims to control advanced breast cancer when standard therapy fails
Disease control
Recruiting now
This study compares a combination of two drugs (elacestrant and capecitabine) to capecitabine alone in people with advanced estrogen receptor-positive breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to one of the two t…
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Jun 17, 2026 00:57 UTC